Arixtra (fondaparinux)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Arixtra (fondaparinux), covering 2010-08-02 to 2010-08-02. Get the full timeline:
Most recent: Clinical Trial Update: Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis) [Phase 3]